While the progression and therapy resistance of MM are known to involve the hyperactivation of key pathways such as PI3K/AKT/mTOR, RAS/MAPK, and NF-κB [41], the specific cascades crucial for P-gp upregulation in response to CFZ remain elusive. The gene discussed is NFKB1; the disease is Miyoshi myopathy.